title: Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccine.
abstract: IgG antibodies against Haemophilus influenzae type b (Hib) capsular polysaccharide (CPS) and tetanus toxoid (TT) were measured for 53 children, 10 years of age, before and 1 month after a booster dose of diphtheria-tetanus vaccine (DT). All children had been vaccinated at 3, 5 and 12 months of age with DT and a Hib-TT conjugate. Geometric mean concentrations of Hib CPS serum IgG antibody were 4.16 and 4.30 microg/mL before and after the DT booster, respectively. The geometric mean concentration of TT IgG antibody increased from 0.09 IU/mL to 4.58 IU/mL (P < 0.001). Hib CPS IgG levels remained well above protective titers for 9 years after 3 doses of Hib-TT appropriately spaced in infancy. A booster dose of TT did not affect Hib CPS antibody concentrations but induced a pronounced IgG response against TT.
authors.affiliation: Department ofInfectious Diseases, Sahlgrenska University Hospital, Sweden.
authors.forename: Bo A
authors.initials: BA
authors.lastname: Claesson
authors.forename: Birger
authors.initials: B
authors.lastname: Trollfors
authors.forename: Teresa
authors.initials: T
authors.lastname: Lagergård
authors.forename: Nina
authors.initials: N
authors.lastname: Knutsson
authors.forename: Rachel
authors.initials: R
authors.lastname: Schneerson
authors.forename: John B
authors.initials: JB
authors.lastname: Robbins
mesh_terms: D000907:Antibodies, Bacterial / Q000032:analysis / Q000276:immunology*; D002352:Carrier Proteins / Q000276:immunology*; D002648:Child; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006192:Haemophilus Infections / Q000276:immunology* / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008297:Male; D012680:Sensitivity and Specificity; D013745:Tetanus Toxoid / Q000008:administration & dosage / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000032:analysis / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D002352:Carrier Proteins; D018073:Haemophilus Vaccines; C055753:Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate